Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 4Breast Neoplasms 3Multiple Myeloma 2Fallopian Tube Neoplasms 2Stomach Neoplasms 1Sarcoma 1Platinum-resistant Recurrent Ovarian Cancer 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Ovarian Cancer Recurrent 1Lymphoma, Follicular 1Lymphoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Ovarian Cancer 1

Interventions

Doxorubicin 62Ifosfamide 39Gemcitabine 29Radiotherapy 27Filgrastim 27Cyclophosphamide 26Docetaxel 19Vincristine 18pembrolizumab 17Etoposide 17pazopanib 16Cisplatin 16Nivolumab 15Trabectedin 14apatinib 13Magnetic Resonance Spectroscopy 13Carboplatin 12Irinotecan 11Bevacizumab 11anlotinib 10Temozolomide 10Surgical Procedures, Operative 10Sirolimus 10camrelizumab 9Sorafenib 9Paclitaxel 9Ipilimumab 9Injections 9Dactinomycin 9Topotecan 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma × 1-dodecylpyridoxal × Clear all
NCT03268772 2020-04-22

PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS

Fudan University

Phase 2 Unknown
40 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡